Flawed Approach to Assessing Value of Myeloma Treatment Puts Patients at Risk

Flawed Approach to Assessing Value of Myeloma Treatment Puts Patients at Risk From the American Society of Clinical Oncology to the Centers for Medicare & Medicaid Services, a growing number of institutions are attempting to assess the cost-effectiveness of myeloma treatments. In his blog this week, IMF Chairman Dr. Brian Durie responds to the hue and cry over the latest such effort, a report entitled “Treatment Options for Relapsed or Refractory Multiple Myeloma.” Its pricing recommendations, writes Dr. Durie, have “serious implications and serious flaws.” To read Dr. Durie's blog, click HERE.
Source: International Myeloma Foundation - Category: Hematology Source Type: news